Willemien F.J. Hof, Jan Freark de Boer, Henkjan J. Verkade
{"title":"治疗进行性家族性肝内胆汁淤积症的新药:II期和III期试验聚焦","authors":"Willemien F.J. Hof, Jan Freark de Boer, Henkjan J. Verkade","doi":"10.1080/14728214.2024.2336986","DOIUrl":null,"url":null,"abstract":"Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders characterized by inappropriate bile formation, causing hepatic accumulation of bile acids and, subsequently, liver injur...","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"1 1","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials\",\"authors\":\"Willemien F.J. Hof, Jan Freark de Boer, Henkjan J. Verkade\",\"doi\":\"10.1080/14728214.2024.2336986\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders characterized by inappropriate bile formation, causing hepatic accumulation of bile acids and, subsequently, liver injur...\",\"PeriodicalId\":12292,\"journal\":{\"name\":\"Expert Opinion on Emerging Drugs\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Emerging Drugs\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14728214.2024.2336986\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Emerging Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14728214.2024.2336986","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials
Progressive familial intrahepatic cholestasis (PFIC) is a group of disorders characterized by inappropriate bile formation, causing hepatic accumulation of bile acids and, subsequently, liver injur...
期刊介绍:
Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.